Abstract:ObjectiveTo investigate the effect of Paroxetine combined with Shenqiwuweizi Granules in the treatment of generalized anxiety disorder(GAD).Methods78 cases of GAD patients treated in our hospital from March 2016 to July 2017 were randomly divided into the study group and the control group,with 39 cases in each group.The control group patients were given the Paroxetine treatment,the study group patients were treated with Shenqiwuweizi Granule on the basis of the control group.The clinical curative effect,the change of Hamilton Anxiety Scale (HAMA)score and the Pittsburgh sleep quality index(PSQI)before and after treatment,the incidence of adverse drug reactions were compared between the two groups.ResultsThe total effective rate of clinical treatment was 97.4%after 8 weeks of treatment in the study group,which was significantly higher than that of the control group of 82.1%(P<0.05).There was no significant difference in the HAMA score and PSQI score before the treatment between the two groups(P>0.05).The HAMA score and PSQI score of the study group decreased significantly at the 1 week after treatment,and the control group began to decrease from the second week after the treatment.The scores of HAMA and PSQI in the study group were significantly lower than those in the control group (P<0.05).There was no statistical difference in the TESS score between the two groups of patients after treatment at different time points(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).ConclusionOn the basis of Paroxetine treatment of GAD,the combination of Shenqiwuweizi Granule can relieve anxiety and depression,and improve the treatment effect,the safety is high,patients will not produce drug dependence,it is worthy of clinical promotion and application.
姚旭东; 刘芳. 帕罗西汀联合参芪五味子颗粒治疗广泛性焦虑障碍的效果[J]. 中国当代医药, 2018, 25(5): 15-17.
YAO Xu-dong; LIU Fang. Effect of Paroxetine combined with Shenqiwuweizi Granule in the treatment of generalized anxiety disorder. 中国当代医药, 2018, 25(5): 15-17.